Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis.

摘要: Sepsis activates the coagulation system and frequently causes hypercoagulability, which is not detected by routine tests. A reliable method to evaluate hypercoagulability thromboelastography (TEG), but this has so far been used investigate sepsis-induced hypercoagulability. Antithrombin (AT) in plasma of septic patients decreased, administration AT may therefore reduce acquired Not clear, however, what extent supraphysiologic levels decrease acute patients. The present study investigates profile before during four day high-dose therapy. Patients with severe sepsis were randomly assigned receive either 6,000 IU as a bolus infusion followed maintenance dose 250 IU/hour over days (n = 17) or placebo 16). TEG, platelet count, fibrinogen levels, prothrombin time activated partial thromboplastin assessed at baseline daily TEG showed both groups baseline, was neither reversed doses AT. mainly caused increased fibrinogen, lesser platelets. Plasmatic similar groups, did change period. current shows distinct suffering from sepsis, treatment days. This finding supports recent data showing that modulation coagulatory activation does occur one week Trial registration: Current Control Trials ISRCTN22931023